Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.

carcinoma in situ
neutrophil count
core needle biopsy
mammogram
  • 46 views
  • 07 Nov, 2020
  • 2 locations
GE-148-002: A Phase 2 Open-label Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Background: - GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear more clearly on imaging scans. Researchers are also interested in determining whether …

  • 36 views
  • 08 Nov, 2020
  • 1 location
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal tract and lung, based on retrospective studies. Nevertheless the prognosis of this group of patients is still poor with median survival of less than 20 months. Everolimus is an mammilian target of rapamycin (mTOR) inhibitor that …

everolimus
ki-67
liver metastasis
neutrophil count
renal function
  • 0 views
  • 23 Jan, 2021
  • 5 locations
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

  • 44 views
  • 11 Mar, 2021
  • 5 locations
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

blood transfusion
carboplatin
breast cancer
ki-67
erbb2
  • 19 views
  • 23 Jan, 2021
  • 1 location
Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma

The current study aims at answering the scientific question, whether exfoliated cells from STICs get transported into the uterine cavity via the fallopian tube, and whether it is possible to detect those cells in the lavage fluid from the uterine cavity and proximal fallopian tubes. To address this question, the …

cancer of the ovary
BRCA1
ovarian cancer
carcinoma
serous cystadenocarcinoma
  • 95 views
  • 10 Apr, 2021
  • 17 locations
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

(e.g., 2 weeks or 4 weeks) preoperative hormone therapy. Ki-67 is most commonly used among these markers. In contrast to the absolute value, the degree of Ki-67 changes which consider the baseline

growth factor
estrogen receptor
epidermal growth factor receptor
breast cancer
tumor cells
  • 1 views
  • 22 Jan, 2021
  • 1 location
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

chemotherapy or neoadjuvant endocrine therapy using tools of nodal status, Ki-67, and multigene assay(Mammaprint)

breast-conserving surgery
her2/neu-negative breast cancer
endocrine therapy
ki-67
erbb2
  • 0 views
  • 21 Mar, 2021
  • 1 location
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

and surgery. This study is designed to assess whether tumor proliferation, as measured by the natural log expression of Ki-67 staining of breast tumor cells, is reduced following approximately

ductal carcinoma in situ
breast surgery
breast cancer
ki-67
tumor cells
  • 12 views
  • 22 Jan, 2021
Personalized CAPTEM Radiopeptide Therapy of Advanced Non-resectable Neuroendocrine Cancer

-entero-pancreatic neuroendocrine tumors, GEP-NET, (G1, G2), in selected cases with high proliferation index (Ki-67> 20%, usually below 55%), NETG3, with overexpression of somatostatin receptor (SSTR

edotreotide
ki-67
temozolomide
neuroendocrine carcinoma
SPECT Scan
  • 5 views
  • 26 Jan, 2021
  • 1 location